EGFR and neoplasm: In the context of metabolic pathways contributing to the development of NSCLC, multiple factors particularly aberrant signaling driven by somatic mutations in the epidermal growth factor receptor (EGFR)-mediated rat sarcoma/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase (RAS/RAF/MAPK), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways have been identified as critical factors leading to tumor survival.